Skeletal muscle

Noom Adds Muscle Defense™ to Its GLP-1 Companion Program to Help Prevent Muscle-Mass Loss While Taking GLP-1s

Retrieved on: 
Giovedì, Maggio 9, 2024
Skeletal muscle, Health, Psychology, Sarcopenic obesity, Pilates, Habit, Yoga, Motivation, Exercise, Movement, Community, HIIT, Management

NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people to live better and healthier lives, launches Noom Move, an on-demand fitness offering, including Muscle Defense™, a curated movement program for those taking GLP-1 medications. In a cutting-edge collaboration with FitOn, the move directly integrates FitOn’s extensive library of fitness programming into the Noom app, making exercise available to all Noom members as they build healthy habits.

Key Points: 
  • In a cutting-edge collaboration with FitOn, the move directly integrates FitOn’s extensive library of fitness programming into the Noom app, making exercise available to all Noom members as they build healthy habits.
  • “Powerful weight-loss meds need a powerful companion,” said Geoff Cook, Chief Executive Officer of Noom.
  • “Muscle mass must be retained to avoid conditions like sarcopenic obesity down the road.
  • Noom Move makes habit-building even easier.”
    Noom Move is now available to all Noom members, including Noom Med and GLP-1 Companion members, supporting medically assisted weight loss to prevent lean muscle mass loss.

Affinia Therapeutics to Present Data on Novel Cardiotropic and BBB-Penetrant AAV Capsids and Preclinical Efficacy and Safety in Genetic Cardiomyopathies and Sporadic ALS at the American Society of Gene & Cell Therapy 2024 Annual Meeting

Retrieved on: 
Lunedì, Aprile 22, 2024
DRG, Heart, Traffic barrier, Computational science, Safety, Abstract (summary), Tropism, Cardiac muscle, MD, Structure, Diagram, Cell, BAG3, AAV, Skeletal muscle, CNS, Senior, Synthetic media, Liver, Gene, Society, ALS, Ataxin-2, BBB, Toxicity, Central nervous system, Messenger, Generative, Transcytosis, Annual general meeting, Therapy, Vaccine

Affinia's novel capsids have favorable manufacturing yields and levels of preexisting population immunity.

Key Points: 
  • Affinia's novel capsids have favorable manufacturing yields and levels of preexisting population immunity.
  • "We are excited to unveil data on our next-generation bespoke capsids that demonstrate robust cardiac transduction while detargeting the liver and DRG.
  • One oral presentation showcases data from Affinia's novel, BBB-penetrant AAV capsid with a potential therapeutic application to sporadic ALS.
  • The first poster showcases data that confirm the novel cardiotropic AAV capsid's safety and therapeutic efficacy in an animal model of cardiac dysfunction with a potential therapeutic application in genetic cardiomyopathies.

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)

Retrieved on: 
Mercoledì, Aprile 10, 2024
Notifiable disease, Metabolism, Obesity, Euronext Growth, Skeletal muscle, Patient, Nature Biotechnology, Weight loss, Trial of the century, OBA, Facial muscles, Sarcopenia, Therapy, MAS, Pharmaceutical industry

These benefical effects of BIO101 (20-hydroxyecdysone) may translate into improved mobility and muscle strength in obese sarcopenic patients, as suggested in the SARA-INT phase 2 study.

Key Points: 
  • These benefical effects of BIO101 (20-hydroxyecdysone) may translate into improved mobility and muscle strength in obese sarcopenic patients, as suggested in the SARA-INT phase 2 study.
  • We believe that our leadership in developing drugs for muscular diseases and promising results obtained in obesity will be a strong accelerator of the OBA clinical plan."
  • The OBA Phase 2 clinical study is expected to start mid 2024, upon regulatory approvals, with first patients expected to be treated in the second half of 2024.
  • Further information on the OBA program and the clinical study is expected to be provided through the coming weeks.

Orphan designation: (6aR,10aR)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid Treatment of dermatomyositis Withdrawn

Retrieved on: 
Martedì, Aprile 9, 2024
Eurostat, Civil service commission, Eating, Diagnosis, Azathioprine, Disease, Dermatomyositis, Risk, Rash, Inflammation, Patient, Committee, Knowledge, Tissue, Regulation, EMA, IRIS, Mouth, European, Skin, COMP, Heart, Sponsor, European Commission, Immune system, Safety, Muscle weakness, Skeletal muscle, Stomach, Marketing, Medicine, Pharmaceutical industry

Orphan designation: (6aR,10aR)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid Treatment of dermatomyositis Withdrawn

Key Points: 


Orphan designation: (6aR,10aR)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid Treatment of dermatomyositis Withdrawn

Burn Boot Camp and Muscular Dystrophy Association Team Up for 8th Annual 'Be Their Muscle' Philanthropic Event

Retrieved on: 
Lunedì, Marzo 25, 2024
Research, Employment, Entrepreneurship, Skeletal muscle, MDA, ALS, Partnership, Air travel, Education, Duke University Hospital, Social media, Muscular dystrophy, Muscular Dystrophy Association, Senior, Empowerment, Duchenne muscular dystrophy, Duchenne, Clinical trial, FDA, Summer camp, Pharmaceutical industry

Charlotte, North Carolina, March 25, 2024 (GLOBE NEWSWIRE) -- Burn Boot Camp, a leading boutique fitness franchise, has teamed up with the Muscular Dystrophy Association (MDA) for its eighth annual national 'Be Their Muscle' philanthropic event.

Key Points: 
  • Charlotte, North Carolina, March 25, 2024 (GLOBE NEWSWIRE) -- Burn Boot Camp, a leading boutique fitness franchise, has teamed up with the Muscular Dystrophy Association (MDA) for its eighth annual national 'Be Their Muscle' philanthropic event.
  • Muscular Dystrophy Association is one of Burn Boot Camp's longest-standing national philanthropic partners," explained Morgan Kline, CEO and Co-Founder of Burn Boot Camp.
  • "Here at the Muscular Dystrophy Association, we stand hand in hand with Burn Boot Camp in our shared commitment to empower communities nationwide.
  • MDA and Burn Boot Camp will be posting throughout the campaign on social media using @MDAorg and @burnbootcamp with #BeTheirMuscle.

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Mercoledì, Marzo 27, 2024
Technology, Biotechnology, FDA, Nanotechnology, Health, Pharmaceutical, Stem Cells, Other Science, Research, Infectious Diseases, Genetics, Fitness & Nutrition, Science, Clinical Trials, Janus, Vivo, Gene editing, Precision BioSciences, Patient, Cash, Mitochondrion, Health care, Infant, NHP, IND, Duchenne muscular dystrophy, Investment, Therapy, ATM, Lilly, Precision, Cell, Skeletal muscle, Hepatitis B, Rachel Haurwitz, Central nervous system, Novartis, Primate, RNA, DNA, Mitochondrial disease, Hepatology, CRISPR, Safety, VWAP, PMM, Food, AAV, Development, Prevail, Publishing, Gene, ASX, University, Diaphragm, OTC, Hemoglobinopathy, IMU, Economics, Administration, Sickle cell disease, PCSK9, CTA, MHRA, Reindeer, Heart, Autoimmune disease, Eli Lilly and Company, DMD

PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.

Key Points: 
  • PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.
  • In November 2023, Precision presented preclinical efficacy and safety data at the 2023 American Association for the Study of Liver Diseases Annual Meeting.
  • Cash and Cash Equivalents: As of December 31, 2023, Precision had $116.7 million in cash and cash equivalents.
  • Revenues: Total revenues for the quarter ended December 31, 2023 were $7.0 million, as compared to $10.6 million for the quarter ended December 31, 2022.

Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference

Retrieved on: 
Lunedì, Marzo 4, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, Molecule, OTCQB, Regeneration, MSCL, TSX, Animal, DMD, Duchenne muscular dystrophy, Facioscapulohumeral muscular dystrophy, Skeletal muscle, Conference, Event, FSHD, Poster, Trauma, Myopathy, Episcopal conference, Face

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today positive preclinical data showing SAT-3247 can improve skeletal muscle function in multiple mouse models of muscle degeneration.

Key Points: 
  • Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today positive preclinical data showing SAT-3247 can improve skeletal muscle function in multiple mouse models of muscle degeneration.
  • In all instances, treatment with SAT-3247 over a three-to-four-week period resulted in a statistically significant improvement in muscle force versus animals receiving placebo.
  • We believe the muscle injury data further expand and broaden the potential for SAT-3247 into non-dystrophy disease indications as well as multiple forms of muscle injury or trauma in otherwise healthy individuals.
  • We continue on our development plan to advance SAT-3247 into first-in-human clinical trials mid-year.”
    These data are being presented in a poster at the 2024 MDA Clinical & Scientific Conference being held March 3-6 in Orlando.

Satellos Announces Upcoming Presentations at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference

Retrieved on: 
Martedì, Febbraio 20, 2024
Health, Stem Cells, Genetics, Clinical Trials, Research, Science, Biotechnology, Molecule, TSX, Poster, Muscular Dystrophy Association, Event, MSCL, MDA, Regeneration, Episcopal conference, Skeletal muscle, Conference, Pharmaceutical industry

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced a late-breaking oral presentation and a poster presentation at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 3-6 in Orlando.

Key Points: 
  • Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced a late-breaking oral presentation and a poster presentation at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 3-6 in Orlando.
  • Title: SAT-3247: An Oral Small Molecule Inhibitor Targeting AAK1, a Critical Effector of Skeletal Muscle Regeneration
    Copies of the presentation and poster will be available after each session on the Events & Presentations page located at: https://ir.satellos.com/events-and-presentations/default.aspx .

Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping

Retrieved on: 
Martedì, Febbraio 20, 2024
Therapy, SAN, Avidity, PMOS, EMA, Orphan drug, Dystrophin, FDA, Food, DMD, Duchenne muscular dystrophy, Weakness, Safety, RNA, Skeletal muscle, European Medicines Agency, Pharmacokinetics, AOC, PMO, Science, Myopathy, Ageing, Pharmaceutical industry

In addition to receiving Rare Pediatric Disease Designation, AOC 1044 has been granted Orphan Designation by the FDA and the European Medicines Agency (EMA), and Fast Track Designation by the FDA.

Key Points: 
  • In addition to receiving Rare Pediatric Disease Designation, AOC 1044 has been granted Orphan Designation by the FDA and the European Medicines Agency (EMA), and Fast Track Designation by the FDA.
  • "We are pleased that the FDA has granted Rare Pediatric Disease designation to AOC 1044, adding to the Orphan Drug and Fast Track designations already granted.
  • Avidity plans to provide a first look at AOC 1044 data in people living with DMD44 in 2H 2024.
  • The EXPLORE44 trial is a randomized, placebo-controlled, double-blind, Phase 1/2 clinical trial to evaluate AOC 1044 in healthy volunteers and participants with DMD mutations amenable to exon 44 skipping (DMD44).

Curious Kids: why do we shiver when we feel cold?

Retrieved on: 
Lunedì, Febbraio 12, 2024
Woman, Hypothermia, Nervous system, Muscle contraction, Temperature, Thermoregulation, Mammal, Skeletal muscle, Bed, Heart, Shivering, Movement, Brain, Running

“Why do we shiver when we feel cold?” – Syeda, age 10, from Karachi

Key Points: 
  • “Why do we shiver when we feel cold?” – Syeda, age 10, from Karachi
    What a cool question, Syeda!
  • If our body temperature drops too low, our heart, nervous system and other organs are not able to work normally.
  • All mammals have the ability to shiver, so your pet cat or dog might shiver when they’re cold too.
  • Read more: Curious Kids: if our bodies are happy at 37℃, why do we feel so unhappy when it's too hot outside?